Early Metabolic Injury – LiSym/EMI


Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. In the coordinated submission from the VLN showcases, pillar I – “Early Metabolic Injury” looks into the transition from steatosis to non-alcoholic steatohepatitis (NASH) as the disease-defining moment in NAFLD: while simple steatosis has a good prognosis, patients with ensuing inflammation are at risk for liver cirrhosis and hepatocellular carcinoma. Building on the steatosis & LIAM showcases and the systems pharmacology clinical trial of VLN, a systems analysis of these early disease events will be performed to elucidate the molecular mechanisms that trigger disease progression: using the VLN biobank long-term followed patients and LiSyM animal models, we will profile the molecular pathways, including a systematic and quantitative analysis of lipids in relation to the structural alterations in liver tissue as determined by high-resolution quantitative imaging. The data will be used to generate models that integrate the molecular alterations with early morphological and pathogenetic changes, and can predict disease progression.


Principal Investigators
Klipp, Edda Prof. Dr. rer. nat. Dr. h.c. (Details) (Theoretical Biophysics)

Duration of Project
Start date: 01/2016
End date: 06/2021

Last updated on 2021-08-02 at 23:05